China’s Weijian Pharma Group obtained China marketing rights to an infertility treatment produced by LG Lifesciences of Korea. The treatment is Follitrope, an ovulation induction product, which increases follicle stimulating hormone (FSH). LG Lifesciences developed Follitrope using its own recombinant DNA methods. Headquartered in Hong Kong, Weijian offers a large portfolio of products to China’s market. Terms of the agreement were not disclosed.
Help employers find you! Check out all the jobs and post your resume.
